AGREEMENT AND PLAN OF MERGER
CUBIST PHARMACEUTICALS, INC.
FRD ACQUISITION CORPORATION
ADOLOR CORPORATION
SECTION 5 - COVENANTS AND AGREEMENTS
SECTION 6 - ADDITIONAL AGREEMENTS
SECTION 8 - TERMINATION, AMENDMENT AND WAIVER
AGREEMENT AND PLAN OF MERGER
THIS AGREEMENT AND PLAN OF MERGER (this “Agreement”) dated as of October 24, 2011 is among CUBIST PHARMACEUTICALS, INC. (“Parent”), a Delaware corporation, FRD ACQUISITION CORPORATION (“Sub”), a newly-formed Delaware corporation and a direct or indirect wholly-owned subsidiary of Parent, and ADOLOR CORPORATION (the “Company”), a Delaware corporation.
SECTION 5 - COVENANTS AND AGREEMENTS
SECTION 6 - ADDITIONAL AGREEMENTS
SECTION 8 - TERMINATION, AMENDMENT AND WAIVER
Tamara L. Joseph, Senior Vice President, General Counsel and Secretary
Exton, PA 19341
John M. Limongelli, Senior Vice President, General Counsel & Secretary
Philadelphia, Pennsylvania 19104
EACH OF PARENT, COMPANY AND SUB HEREBY IRREVOCABLY WAIVES THE RIGHT TO A TRIAL BY JURY IN ANY ACTION, PROCEEDING OR COUNTERCLAIM (WHETHER BASED IN CONTRACT, TORT OR OTHERWISE) ARISING OUT OF, UNDER OR IN CONNECTION WITH THIS AGREEMENT OR ANY RELATED DOCUMENT, OR ANY COURSE OF CONDUCT, COURSE OF DEALINGS, STATEMENT OR ACTION RELATED HERETO OR THERETO.
ADOLOR CORPORATION
CUBIST PHARMACEUTICALS, INC.
FRD ACQUISITION CORPORATION
TENDER AND VOTING AGREEMENT
THIS TENDER AND VOTING AGREEMENT (this “Agreement”) dated [                              ], 2011, is entered into between Cubist Pharmaceuticals, Inc., a Delaware corporation (“Parent”), FRD Acquisition Corporation, a Delaware corporation and direct or indirect wholly owned subsidiary of Parent (“Sub”), and                                                   , (“Stockholder”), with respect to (i) the shares of common stock, par value $0.0001 per share (the “Shares”), of Adolor Corporation a Delaware corporation (the “Company”), (ii) all securities exchangeable, exercisable or convertible into Shares, and (iii) any securities issued or exchanged with respect to such Shares, and upon any recapitalization, reclassification, merger, consolidation, spin-off, partial or complete liquidation, stock dividend, split-up or combination of the securities of the Company or upon any other change in the Company’s capital structure, in each case whether now owned or hereafter acquired by the  Stockholder (collectively, the “Securities”).
WHEREAS, Parent, Sub and the Company have entered into an Agreement and Plan of Merger dated as of the date hereof (the “Merger Agreement”) pursuant to which Sub has agreed to make a tender offer described therein and thereafter merge with and into the Company (the “Merger”) with the result that the Company becomes a wholly owned subsidiary of Parent;
Tamara L. Joseph, Senior Vice President, General Counsel and Secretary
CUBIST PHARMACEUTICALS, INC.
FRD ACQUISITION CORPORATION
SCHEDULE I TO
THE TENDER AND VOTING AGREEMENT
CERTIFICATE OF INCORPORATION
[COMPANY]
The name of the corporation is:  [COMPANY]
CONTINGENT PAYMENT RIGHTS AGREEMENT
THIS CONTINGENT PAYMENT RIGHTS AGREEMENT, dated as of                         , 2011 (this “Agreement”), is entered into by and between Cubist Pharmaceuticals, Inc., a Delaware corporation (“Parent”), and Broadridge Corporate Issuer Solutions, Inc., a Pennsylvania corporation, as Rights Agent.
Broadridge Corporate Issuer Solutions, Inc.
1717 Arch Street
Suite 1300
Philadelphia, Pennsylvania 19103
Broadridge Financial Solutions, Inc.
2 Journal Square Plaza
Jersey City, New Jersey 07306
Attention: General Counsel
Cubist Pharmaceuticals, Inc.
65 Hayden Avenue
Lexington, Massachusetts 02421
Tamara L. Joseph, Senior Vice President,
General Counsel and Secretary
CUBIST PHARMACEUTICALS, INC.
BROADRIDGE CORPORATE ISSUER SOLUTIONS, INC.
POTENTIAL MILESTONE PAYMENT AMOUNTS
NEITHER FDA, NOR EMA,
PREFERRED PRODUCT
LABEL APPROVAL
EMA PREFERRED PRODUCT
LABEL APPROVAL ONLY
